Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
europe blog main
europe top stories
8
×
life sciences
national blog main
8
×
national top stories
startups
8
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
boston top stories
fda
cancer
deals
gilead sciences
merck
amag pharmaceuticals
astrazeneca
cancer immunotherapy
pfizer
What
bio
roundup
sciences
acquisitions
amid
bombast
bristol
buy
cancer
caught
ceo
coronavirus
covid
daniel
debate
debut
develop
discussion
efforts
gilead
ipo
life
medicines
meso’s
miss
moves
o’day
pandemic
pfizer’s
presidential
promise
response
tuesday’s
vaccine
viewers
week
activity
alliance
amsterdam
announced
Language
unset
8
×
Current search:
unset
×
startups
×
" national blog main "
×
" europe top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More